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INTRODUCTION
Lower respiratory tract infections (LRTIs), which are fre-
quently caused by viruses, are one of the leading causes of
morbidity and mortality in children worldwide (Woensel et
al., 2003). Every year in the United States approximately
30 000 children are hospitalised during their first year of
life due to viral lower respiratory tract infections (Shay et
al, 1999). Moreover, in developing countries each year up
to 1.8 million children die due to acute respiratory diseases
(Mathers et al., 2008). Only about 40% of lower respiratory
tract viral illnesses have an aetiologically identifiable agent
(Kahn, 2007). Also in Latvia and Lithuania there is a seri-
ous health care problem regarding respiratory tract diseases
in the children population. Data from the Disease Preven-
tion and Control Centre show that respiratory tract diseases
in children under one year of age take the first place in the
structure of morbidity. It is also important that during the
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Human bocavirus 1 (HBoV1) is a parvovirus recently found to be a possible aetiologic agent of
acute respiratory disease in children. We conducted the first clinical and molecular study on this
virus in Latvia (LV) and Lithuania (LT). The aim of the study was to determine the occurrence of
HBoV1 in respiratory tract samples taken from hospitalised children with acute respiratory tract in-
fections in LV and LT. In total 186 children with age one to 50 months, and who fulfilled criteria of
acute respiratory tract infection, including lower respiratory tract infections, with or without fever,
were included in this study. A nasopharyngeal aspirate was obtained from each patient on admis-
sion. DNA was isolated and polimerase chain reaction (PCR) performed targeting the HBoV1
NS1sequence. HBoV1 positive samples were sequenced and phylogenetic analysis was per-
formed. HBoV1 sequence was detected in 42 (32%) of 130 LV and in 8 (14%) of 56 LT samples.
In LV the majority of patients with HBoV1 infection were observed in February while in LT in Octo-
ber. The phylogenetic tree for HBoV1 indicated that isolates of HBoV1 cluster closely and include
almost all of the isolates in this study. HBoV1 is common in Latvia and Lithuania and might be a
significant pathogen that contributes to acute respiratory tract infections in children.
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198 Proc. Latvian Acad. Sci., Section B, Vol. 70 (2016), No. 4.
last four years there have been more cases not only with
acute upper respiratory tract infections but also with lower
respiratory tract infections.
Human bocavirus (HBoV) was first discovered in 2005 by
Tobias Allander and colleagues in Sweden in pooled respi-
ratory samples from children with respiratory tract infection
(Allander et al., 2005). HBoV belongs to the Parvoviridae
family, Parvovirinae subfamily, Bocaparvovirus genus
(Yoo et al., 2015). Parvoviridae family members are small,
non-enveloped viruses with isometric nucleocapsids (di-
ameters of 18 to 26 nm), which contain a single molecule of
linear, negative-sense or positive-sense, single-stranded
DNA. The complete genome size of HBoV1 is 4000 to
6000 nucleotides. Three open reading frames are found in
the genome. Of them, two encode non-structural proteins
(NS1 and NP1) and one encodes two capsid proteins (VP1
and VP2) (Allander et al., 2005).
So far four types of HBoV are known (Allander et al., 2005;
Kapoor et al., 2009; 2010). HBoV type 1 (HBoV1) is a res-
piratory virus and has been associated with both acute upper
and lower respiratory tract infections (Allander et al., 2007;
Söderlund-Venermo et al., 2009; Christensen et al., 2010).
HBoV1 has a worldwide distribution and has been detected
in Europe, Africa, Asia, North America, Australia, and the
Middle East. No racial and gender predilection is known.
The prevalence of HBoV1 in respiratory tract secretions
ranges from 1.5 up to 22% (Bastien et al., 2006; Li et al.,
2013). However, one study showed prevalence of HBoV1
in respiratory tract secretions to be as high as 59% of pa-
tients (Martin et al., 2010).
So far, the occurrence of HBoV1 has not been investigated
in Latvia and Lithuania. Taking into account the high mor-
bidity of acute respiratory tract diseases in children, it is im-
portant to determine the occurrence of HBoV1infection in
Latvia and Lithuania.
Thus, the aim of this study was to determine the occurrence
of the HBoV1 genomic sequence in respiratory tract sam-
ples taken from hospitalised children with acute respiratory
tract infections in Latvia and Lithuania. Sequences of
HBoV detected in the present study were further character-
ised for their genetic evolutionary relationships with the vi-
ruses circulating in this area and HBoV reference strains.
The phylogenetic analysis was conducted by our collegues
from Taiwan.
MATERIALS AND METHODS
Study subjects and inclusion criteria. The study was per-
formed in the Children’s Clinical University Hospital of
Rîga, Latvia, from November 2012 to June 2015 (there
were no patients in summer months due to lack of hospita-
lised patients with LRTIs) and in the Children‘s Hospital,
Affiliate of Vilnius University Hospital Santariskiu
Klinikos, Lithuania, from September 2013 to March 2014.
Children aged one to 50 months who were hospitalised in
the Paediatric Department and fulfilled the criteria of acute
respiratory tract infection (ARTI), including LRTI, with or
without fever, were included in this prospective study. Fe-
ver was defined as a core temperature 38 °C. LRTI was
defined according to the clinical definition criteria and/or
chest roentgenogram with positive results (infiltrates). Ac-
cording to the clinical definition of LRTI, at least one spe-
cific lower respiratory tract sign from the following (Roth et
al., 2008) should be positive: fast or difficulty in breathing;
chest wall in drawing; abnormal auscultator findings (crack-
les/crepitation or bronchial breath sounds).
On inspection, fast breathing or tachypnea was defined
based on the World Health Organisation (WHO) criteria:
respiratory rate > 60 per minute in children aged < 2
months, > 50 per minute in children aged 2–12 months, and
40 per minute in children aged 12–60 months (Anonymous,
1995).
A total of 130 children [74 (57%) male and 56 (43%) fe-
male, with mean age 15 ± 11 months (range 1 to 50
months)] from Latvia and 56 children [40 (70%) male and
16 (30%) female, with mean age 25 ± 14 months (range 4 to
48 months)] from Lithuania were included in this study.
The study protocol was approved by the Ethics Committee
of the Rîga Stradiòð University and by the Ethics Commit-
tee for Vilnius Regional Biomedical Research. Written in-
formed consent was obtained from the parents of all partici-
pating children.
Laboratory methods. All clinical samples were tested in
the corresponding home country according to a previously
agreed work plan using common methods.
Human DNA was extracted from 187 nasopharyngeal aspi-
rates (NPAs) by phenol-chloroform extraction. The quantity
of DNA was measured spectrophotometrically, and the
quality of DNA was tested using -globin gene polimerase
chain reaction (PCR). The HBoV1 NS1 gene sequence was
identified in extracted DNA using a qualitative PCR method
with HBoV1 specific primers (Sloots et al., 2006) with sub-
sequent electrophoretical analysis of PCR products in 1.5%
agarose gel.
Sequencing of HBoV1 specific PCR product. HBoV1 was
confirmed in NPAs DNA by sequencing of PCR products.
The Latvian researcher group analysed the samples accord-
ing to the following protocol: VP1 gene sequencing reac-
tions were performed using a Big Dye Terminator kit (Ap-
plied Biosystems, USA) and the ABI 3100, sequencer.
Nested PCR primers (Kapoor et al., 2010) were used
(5’-3’): AK-VP-F1, CGCCGTGGCTCCTGCTCT and
AK-VP-F2, TGTTCGCCATCACAAAAGATGTG for the
first round of amplification, AK-VP-R1,
GGCTCCTGCTCTAGGAAATAAAGAG and AK-VP-R2,
CCTGCTGTTAGGTCGTTGTTGTATGT for the second
round of amplification and for sequencing of both amplified
DNA strands.
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In Lithuania, sequencing of the PCR product was conducted
with another protocol using primers A, B, C, D, D1, and D2
(Fig. 1, Table 1).
PCR products were purified from the agarose gel using a
GeneJET™ Gel Extraction Kit, cloned into pJET 1.2 vector
using the CloneJET PCR Cloning Kit (Thermo Fisher Sci-
entific, Lithuania) and transformed into E. coli DH5a cells.
Plasmid DNA was isolated and tested by restriction diges-
tion.
The sequencing was performed in BaseClear company
(Netherlands) directly from PCR products using the same
primers as for PCR or from plasmids using the pJET1.2 for-
ward and reverse sequencing primer.
Phylogenetic analysis. Thirty-one strains of HBoV partial
VP1 gene (487bp) from Taiwan, Latvia, and Lithuania were
used to construct a phylogenetic tree. VP genes were
aligned by Muscle implemented in the MEGA 6 software
(Tamura et al., 2013). To ensure the consistency of tree to-
pologies, the phylogenetic trees were reconstructed with the
neighbour-joining (NJ) and maximum likelihood (ML)
methods using MEGA 6 and PhyML 3.0 (Guindon et al.,
2010; Tamura et al., 2013). The robustness of the phylogen-
etic trees was statistically evaluated by bootstrap analysis
with 1000 replicates. A bootstrap value > 75% was consid-
ered to represent a monophyletic group.
Statistical analysis. The statistical analysis was performed
using GraphPad Prism 6.0. software. Fisher’s exact test was
performed to assess the significance of differences. A p
value < 0.05 was considered statistically significant. For the
analysis of patient data, descriptive statistics were used.
RESULTS
A total of 186 patients were enrolled in the study. The mean
age for patients from Latvia (LV) was 15 ± 11 months and
for patients from Lithuania (LT) — 25 ± 14 months. Forty-
two (32%) of the 130 patients (74 male and 56 female) who
were recruited in LV were found to be positive for HBoV1
by PCR and subsequent sequencing. Of the 42 positive pa-
tients, more were males (62%) than females (p = 0.048).
In order to assess HBoV1 prevalence among age groups, we
divided the patients into four groups: 1st group: 0–6 months
(n = 29; 19 male and 10 female), 2nd group: 6–12 months (n
= 28; 12 male and 16 female), 3rd group: 12–24 months (n =
48; 29 male and 19 female) and 4th group: 24–60 months (n
= 25; 14 male and 11 female). There were significantly
more patients in the 3rd group in comparison to the 1st (p =
0.014), 2nd (p = 0.009) and 4th group (p = 0.002).
Of the 29 patients in the 1st age group, the HBoV1 sequence
was detected in NPAs DNA samples in four male and three
female patients; from 28 patients in the 2nd age group — in
seven male and four female NPAs DNA. Peak prevalence
of HBoV1 infection was observed in patients ranging from
12 to 24 months (eight male and seven female patients of 48
patients, respectively). In the 4th age group, the HBoV1 se-
quence was detected in seven male and two female patients
of 25 patients in total. There was no statistical difference
between distribution by gender in age groups of positive pa-
tients. Age distribution of patients with and without pres-
ence of the HBoV1 genomic sequence in NPAs DNA as a
percentage is shown in Figure 2.
The HBoV1 genomic sequence was detected in samples ob-
tained throughout the year (excepting summer) with the de-
tection rate being the highest in February (21/42, 50%), fol-
lowed by September (5/42, 11.9%) and January (5/42,
11.9%) (Fig 3).
200 Proc. Latvian Acad. Sci., Section B, Vol. 70 (2016), No. 4.
T a b l e 1
PRIMERS FOR HBOV1 CODING SEQUENCES ANALYSIS
Target Primer Orientation Sequence (5'  3')




CCA CGC TTG TGG TGA GTC TA
GCA TGC CCA AGA CTT GTT CT




GCC TAG CTG CGT CTT CTG TT
GTC TCA GGC TCG GTG TCT TC




CCA GCA AGT CCT CCA AAC TC
CGC GAT CAG CGT TAT TTA CA




GAT AAC TGA CGA GGA AAT G
GAG ACG GTA ACA CCA CTA












Fig. 1. Localisation of PCR products that were used for sequencing of the
complete HBoV genome. NS1, NP-1, VP1 and VP2 — DNA sequences
that encode corresponding virus proteins. A, B, C, D, D1, D2 — PCR
products that were cloned and used for sequencing.
Of the 56 patients from LT, significantly more (p = 0.0001)
were male (n = 40) than female (n = 16).
Eight patients of 56 (14%) were positive for HBoV1 se-
quence in NPAs DNA. Of these eight patients, there was no
significant difference in distribution male (n = 5) and fe-
male (n = 3) patients.
Patients from LT were divided into age groups: 1st group:
0–6 months (n = 6; 4 male and 2 female), 2nd group: 6–12
months (n = 6; 5 male and 1 female), 3rd group: 12–24
months (n = 19; 17 male and 2 female) and 4th group:
24–60 months (n = 25; 14 male and 11 female). The size of
the 4th and 3rd groups in comparison to the 1st and 2nd
group was significantly larger (p = 0.0001 and p = 0.0057,
4th versus 1st and 3rd versus 2nd, respectively).
The prevalence of HBoV1 infection per age group in chil-
dren aged 0–60 months was as follows: 1 female of 6 pa-
tients in the 1st group, none in the 2nd group, 1 female and 3
male among 19 patients in the 3rd group and 1 female and 2
male among 25 patients in the 4th group. The age distribu-
tion of patients with and without presence of the HBoV1
genomic sequence in NPAs DNA as percentages is shown
in Figure 4.
Researchers from LT obtained samples only from Septem-
ber 2013 till March 2014. The highest prevalence of
HBoV1 infection in patients from Lithuania was in October
(37.5% of all positive patients) following by September and
January (25% of positive cases) (Fig 5).
HBoV isolates from LV and LT were sequenced to perform
phylogenetic analysis using the partial VP coding region.
The phylogenetic tree for HBoV indicated that isolates of
HBoV1 clustered closely. The gene diversity of HBoV1 iso-
lates was significantly low (0~0.9%) between Taiwan, Lat-
via and Lithuania (Fig. 6).
DISCUSSION
This is the first report on prevalence of HBoV1 in Latvia
and Lithuania. The proportion of HBoV1-positive cases
among children with acute respiratory tract infection, in-
cluding lower respiratory tract infection, was 14% in
Lithuania, which is similar to that reported in Spain, where
17.8% of children with pneumonia were HBoV positive
(Garsia et al., 2018) and Norway, where 25% of children
with acute respiratory tract infections were positive for
HBoV (Christensen et al., 2013). Our colleagues from Tai-
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Fig. 2. Age distribution of patients with and
without presence of HBoV1 in Latvia.
Fig. 3. Monthly distribution of HBoV1 in-
fection prevalence in Latvia.
wan in their first report on HBoV infection in Taiwan also
reported that nearly 10% of children less than two years old
with LRTIs were positive for HBoV. Results from Taiwan-
ese colleagues reflect percentage of HBoV positive patients
with no co-infections (Jih-Hui et al., 2009). However,
HBoV1 was widespread in Latvia (32%). We have no evi-
dence of co-infection, and further studies are required to de-
termine if other viruses or bacteria can cause acute respira-
tory tract infections, including LRTIs. However, we expect
that in the HBoV1 positive cases there was more than one
infectious agent. One of the reasons for the relatively high
proportion of HBoV1 positive cases in Latvian patients
might be due to the selection criteria of children with AR-
TIs including LRTIs. Martin and co-authors, in 2010, re-
ported that HBoV occurred in 33% cases of ill children, but
that presence of the virus was not associated with the pres-
ence of a respiratory illness or with specific respiratory
symptoms (Martin et al., 2010).
In our study we showed that in the LV group of patients
with HBoV1 there were significantly more male (62%) than
female (p = 0.048) patients. In another study, 73.1% of male
patients with respiratory symptoms were found to be posi-
tive for HBoV (Jang Su et al., 2011). However, there was
no significant difference in gender distribution among pa-
tients positive for HBoV1 in the LT group (p = 0.619).
Among HBoV1 positive children, in LV and in LT the ma-
jority of patients were 12 to 24 month old (35.7% and 50%
of positive cases, respectively). Other studies have shown
that HBoV is found in patients 5–6 months of age and older
(Allander et al., 2005; Sloots et al., 2006); some authors
suggested that maternal antibodies might prevent neonatal
infection with HBoV (Ma et al., 2006; Garcia-Garcia et al.,
2007). However, we identified HBoV1 also among infants
younger than 3 months of age, suggesting incidence of
HBoV infection very early in life. In the USA, HBoV has
been detected in children as early as a few days after birth
(Ghietto et al., 2012) and a seroepidemiological study also
provided evidence that HBoV infection is common during
early infancy (Kahn et al., 2008).
HBoV1 infection peak prevalence in LV and LT groups
slightly differed. In LV the majority of patients with
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Fig. 4. Age distribution of patients with
and without presence of HBoV1 in Lithu-
ania.
Fig. 5. Monthly distribution of HBoV1
infection prevalence in Lithuania.
HBoV1 were hospitalised in February while in LT in Octo-
ber. Both of these months are in cold season when we can
expect more patients with ARTIs or LRTIs. The HBoV pos-
itive cases occurred from autumn through spring. There
were no samples taken in our study during summer months
due to lack of hospitalised patients with acute respiratory
tract infections. The seasonal pattern of HBoV occurrence
has been previously reported (Kesebir et al., 2006; Sloots et
al., 2006) although some studies found that HBoV occurs
throughout the year with a spring outbreak (Bastien et al.,
2006).
Within the small region of study, the phylogenetic analysis
indicated close relationship between the Latvian and Lithua-
nian HBoV isolates. The isolated viruses from Latvia are
phylogenetically close not only to some Swedish and
Lithuanian isolates, but also to Taiwanese isolates, indicat-
ing the global nature of HBoV1 distribution.
At present, there is little information on the role of HBoV1
in the aetiopathogenesis of respiratory tract diseases or dis-
ease severity depending on HBoV1 loads and co-infection.
However, the stable rate of HBoV1 infection in autumn and
winter indicates that HBoV1 is an important pathogen for
hospitalised children suffering from acute respiratory tract
infections, including lower respiratory tract infections.
Further investigation should be conducted to examine the
importance of HBoV1 and other co-infecting viruses on res-
piratory tract diseases.
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CILVÇKA BOKAVÎRUSA 1 KLÂTBÛTNE LATVIJÂ UN LIETUVÂ HOSPITALIZÇTIEM BÇRNIEM AR AKÛTÂM ELPCEÏU
SLIMÎBÂM
Pirmâ tipa cilvçka bokavîruss (HBoV1) ir parvovîruss, kas tiek uzskatîts par iespçjamu etioloìisku faktoru akûtu respiratoru slimîbu
gadîjumâ bçrniem. Mçs veicâm pirmo klînisko un molekulâro pçtîjumu par HBoV1 infekcijas sastopamîbu Latvijâ (LV) un Lietuvâ (LT).
Raksta mçríis bija noskaidrot HBoV1 klâtbûtni respiratorâ trakta paraugos, kas iegûti no hospitalizçtiem bçrniem ar akûtâm elpceïu
slimîbâm LV un LT. Pçtîjumâ iekïauti 186 hospitalizçti bçrni vecumâ no 1 lîdz 50 mçneðiem ar akûtâm elpceïu slimîbâm. Tika iegûts
nazofaringeâlâ aspirâta paraugs bçrna pirmajâ stacionçðanas dienâ, izolçta DNS un noteikta HBoV1 NS1 sekvences klâtbûtne, lietojot
polimerâzes íçdes reakciju. Pozitîvie HBoV1 paraugi sekvencçti un veikta filoìençtiskâ analîze. HBoV1 konstatçja 42 (32%) no 130 LV un
8 (14%) no 56 LT paraugos. Latvijâ HBoV1 bieþâk atrada paraugos, kas òemti februârî, bet Lietuvâ — oktobrî. Filoìençtiskâ analîze
parâdîja, ka HBoV1 izolâti ir cieði radniecîgi viens otram. HBoV1 cirkulç Latvijâ un Lietuvâ un, iespçjams, ir nozîmîgs patogçns, kas
iesaistîts akûtu elpceïu infekciju izraisîðanâ bçrniem.
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